

Clarissa Corinaldesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4283668/publications.pdf>

Version: 2024-02-01

14
papers

388
citations

932766

10
h-index

1199166

12
g-index

15
all docs

15
docs citations

15
times ranked

688
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	117
2	Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. <i>Inflammation</i> , 2016, 39, 1238-52.	1.7	46
3	Vitamin D in autoimmune rheumatic diseases: A view inside gender differences. <i>Pharmacological Research</i> , 2017, 117, 228-241.	3.1	35
4	Association of circulating CXCL10 and CXCL11 with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1845-1846.	0.5	34
5	Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2020, 22, 286.	1.6	27
6	Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 143-151.	1.8	26
7	Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 167, 169-181.	1.2	26
8	Transforming Growth Factor β 2 Activation Primes Canonical Wnt Signaling Through Downregulation of Axin2. <i>Arthritis and Rheumatology</i> , 2018, 70, 932-942.	2.9	25
9	Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 920-929.	0.5	23
10	The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism. <i>Endocrine</i> , 2018, 59, 602-613.	1.1	15
11	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2894.	1.8	9
12	Tracking Immunoglobulin Repertoire and Transcriptomic Changes in Germinal Center B Cells by Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 818758.	2.2	4
13	228A monoclonal antibody against BDCA-2 inhibits TLR-induced activation of human pDC in vitro and in vivo: a novel therapeutic target for systemic sclerosis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
14	THU0020A...COMPARATIVE STUDY OF THE PHOSPHODIESTERASE TYPE 5 INHIBITOR SILDENAFIL AND THE PROSTACYCLIN ANALOGUE ILOPROST ON IP10 MODULATION IN SYSTEMIC SCLEROSIS. , 2019, , .		0